Suvorexant to treat alcohol use disorder and comorbid insomnia: Plan for a phase II trial

  title={Suvorexant to treat alcohol use disorder and comorbid insomnia: Plan for a phase II trial},
  author={Erin J. Campbell and Amanda Norman and Yvonne Ann Bonomo and Andrew J. Lawrence},
  journal={Brain Research},

New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies

This review aims to synthesise literature for new approved and emerging pharmacotherapies for AUD and strategies for improving the translational pipeline include drug repurposing and utilisation of human acute laboratory models.

Understanding the Role of Orexin Neuropeptides in Drug Addiction: Preclinical Studies and Translational Value

Treatments that target the orexin system may be a promising strategy to reduce drug intake, mitigate relapse vulnerability, and restore “normal” physiological functions, including feeding and sleep.

Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder

Overall, there remains a great need to improve access to treatment, increase the menu of approved pharmacological treatments, and de-stigmatize and increase treatment-seeking for AUD.

Insomnia due to drug or substance abuse and dependence

Hypocretins (orexins): The ultimate translational neuropeptides

Circuit neuroscience findings suggest that the Hcrt system is a hub that integrates diverse inputs modulating arousal and conveys this information to multiple output regions and highlights the potential of the HCrt system as a therapeutic target for a number of disorders.

Targeting the Orexin System for Prescription Opioid Use Disorder

A review discusses recent preclinical studies that suggest that orexin receptor blockade could be beneficial for the treatment of prescription opioid use disorder.

Acute Cognitive Effects of the Hypocretin Receptor Antagonist Almorexant Relative to Zolpidem and Placebo: A Randomized Clinical Trial.

The data provide support for the hypothesis that hypocretin receptor (Hcrt) antagonists produce less functional impairment than a benzodiazepine receptor agonist (BzRA).

Ethanol Neurotoxicity



New steps for treating alcohol use disorder

New medications, the emergence of digital technology, and other novel approaches such as transcranial magnetic stimulation are discussed with reference to treatments already in practice, and how individual differences in genotype and phenotype may affect outcomes are considered.

Effect of suvorexant on event-related oscillations and EEG sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal

It is suggested that suvorexant has overall sleep-promoting effects, but it may exacerbate some aspects of sleep and EEG pathology.

A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia.

Gabapentin significantly delayed the onset to heavy drinking, an effect which persisted for 6 weeks after treatment ended, and gabapentin had no differential effects on sleep as measured by either subjective report or polysomnography.

Alcohol Detoxification and Relapse Prevention Using Valproic Acid Versus Gabapentin in Alcohol-dependent Patients

The results of this randomized trial suggest that the anticonvulsants were not significantly better than placebo in treating mild withdrawal symptoms, did not influence relapse to alcohol and did not treat the symptoms of depression and sleep disturbance that occur in the postwithdrawal period.

Suvorexant as an Adjunctive Treatment for Insomnia Prior toDiscontinuation of Benzodiazepines: Prevention of Withdrawal Syndromeand Rebound Insomnia

It was observed that concurrent use of BZD was not related to withdrawal from suvorexant in patients being treated for insomnia.

Insomnia, self-medication, and relapse to alcoholism.

Investigation of the frequencies of insomnia and its self-medication with alcohol in a group of alcoholic patients, as well as the relationship of these variables to alcoholic relapse found insomnia remained a robust predictor of relapse after application of logistic regression analysis to control for other variables.

More Treatments on Deck for Alcohol Use Disorder.

Thirteen years have passed since the US Food and Drug Administration (FDA) last approved a new medication to help the nation’s millions of people with alcohol use disorder (AUD) stop or moderate

Alcohol use disorder and sleep disturbances: a feed-forward allostatic framework

Sleep pathology contributes to AUD pathology, and vice versa, possibly as a feed-forward drive to an unrecognized allostatic load that drives the addiction process.